



Dynamic albumin values as clinical surrogate for COVID-19 therapeutics

Johanna S van Zyl ^{1,2}, Joost Felius,^{1,2} Amit Alam,^{2,3,4} Shelley A Hall,^{2,3,4} Aayla K Jamil,^{1,2} Cedric W Spak,^{5,6} Robert L Gottlieb ^{1,2,3,4,7}

¹Baylor Scott & White Research Institute, Baylor Scott & White Health, Dallas, Texas, USA

²Texas A&M University Health Science Center, Dallas, Texas, USA

³Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, Texas, USA

⁴Division of Cardiology, Baylor University Medical Center, Dallas, TX, USA

⁵Division of Infectious Disease, Baylor University Medical Center, Dallas, Texas, USA

⁶Texas Centers for Infectious Disease Associates, Dallas, Texas, USA

⁷Division of Precision Medicine, Baylor University Medical Center, Dallas, TX, USA

Correspondence to

Dr Robert L Gottlieb, Center for Advanced Heart and Lung Disease, 3410 Worth St, Suite 250, Baylor University Medical Center, Dallas, TX 75246, USA; robert.gottlieb@bswhealth.org

Accepted 31 March 2021
Published Online First 28 May 2021



► <http://dx.doi.org/10.1136/jim-2021-001881>
► <http://dx.doi.org/10.1136/jim-2020-001525>



© American Federation for Medical Research 2021. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: van Zyl JS, Felius J, Alam A, et al. *J Investig Med* 2021;**69**:1260.

We are delighted to see a letter to the editor¹ essentially agreeing with the message conveyed through our retrospective observation: that a dynamic, accelerated fall of albumin levels in patients admitted with severe COVID-19 predicts progression to critical COVID-19.² Our express intent was to spur further clinical investigation.

Our conclusion remains unchanged after accounting for pre-existing liver disease. COVID-19 frequently causes a self-limited transaminitis in patients without liver disease. Liver function measured at hospital admission using alanine aminotransferase and aspartate aminotransferase for the patients in our study who progressed to critical disease, compared with those who did not progress, was similar (table 2 in ref 2), and the prevalence of hepatic failure during the course of the admission by baseline disease severity was also similar.

We studied patients admitted for management of COVID-19. Thus, dynamic changes clearly reflect COVID-19 disease. We posited that albumin levels fall dynamically due to the hyperinflammatory pathophysiology of COVID-19, with attendant capillary leak.² We are delighted that the author of the above letter shares our burning question: does the dynamic fall of serum albumin track the hyperinflammatory markers of C-reactive protein, ferritin, and interleukin 6 (IL-6), and do immunomodulators such as glucocorticoids or anti-IL-6 receptor or anti-IL-6 cytokine monoclonal antibody therapies reverse this? This is an important avenue for future investigation. As IL-6 values are not routinely measured, that question can only be addressed prospectively.

Finally, we direct the letter writer to the discussion section of our published manuscript, where we have expressly addressed the potential that glucocorticoids might attenuate the finding we observed. Steroids,³ and possibly other immunomodulators, favorably impact clinical outcomes in patients hospitalized with severe COVID-19 pneumonia and hypoxemia, appearing to

attenuate the dynamic decline and/or spur recovery of serum albumin levels (unpublished observation). Steroids being standard of care now for these hypoxemic inpatients, prospective randomized analysis would be unfeasible for steroids due to absence of equanimity, yet tractable for assessment with add-on immunomodulation.

The closing of our original manuscript rings true today: ‘Finally, we propose that the variables of interest identified in our risk model should be included as risk markers in future treatment studies for COVID-19.’²

We hypothesize that interventions of clinical benefit in COVID-19 will attenuate or reverse the dynamic decline in serum albumin levels, and propose that this signal may be a surrogate, early marker for clinical efficacy of therapies for COVID-19.

Contributors Response first draft by RLG. Major revisions by JSvZ and JF with agreement and concurrence of all authors. All authors have discussed content and approved response.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iDs

Johanna S van Zyl <http://orcid.org/0000-0003-4205-9214>
Robert L Gottlieb <http://orcid.org/0000-0001-8376-8709>

REFERENCES

- 1 Bath SK. Correlation of rate of serum albumin decline with other acute phase reactants and effect of current treatment options on serum albumin level in COVID-19. *J Investig Med*.
- 2 van Zyl JS, Alam A, Felius J, et al. ALLY in fighting COVID-19: magnitude of albumin decline and lymphopenia (ALLY) predict progression to critical disease. *J Investig Med* 2021;**69**:710–8.
- 3 RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with COVID-19. *N Engl J Med* 2021;**384**:693–704.